全文获取类型
收费全文 | 11745篇 |
免费 | 543篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 481篇 |
妇产科学 | 322篇 |
基础医学 | 899篇 |
口腔科学 | 184篇 |
临床医学 | 915篇 |
内科学 | 3083篇 |
皮肤病学 | 147篇 |
神经病学 | 863篇 |
特种医学 | 302篇 |
外科学 | 1436篇 |
综合类 | 109篇 |
预防医学 | 1842篇 |
眼科学 | 106篇 |
药学 | 397篇 |
中国医学 | 2篇 |
肿瘤学 | 1173篇 |
出版年
2023年 | 542篇 |
2022年 | 754篇 |
2021年 | 891篇 |
2020年 | 1009篇 |
2019年 | 528篇 |
2018年 | 506篇 |
2017年 | 549篇 |
2016年 | 575篇 |
2015年 | 527篇 |
2014年 | 1051篇 |
2013年 | 735篇 |
2012年 | 417篇 |
2011年 | 317篇 |
2010年 | 656篇 |
2009年 | 633篇 |
2008年 | 248篇 |
2007年 | 303篇 |
2006年 | 241篇 |
2005年 | 216篇 |
2004年 | 160篇 |
2003年 | 157篇 |
2002年 | 177篇 |
2001年 | 152篇 |
2000年 | 121篇 |
1999年 | 136篇 |
1998年 | 94篇 |
1997年 | 77篇 |
1996年 | 89篇 |
1995年 | 32篇 |
1994年 | 27篇 |
1993年 | 33篇 |
1992年 | 58篇 |
1991年 | 41篇 |
1990年 | 50篇 |
1989年 | 35篇 |
1988年 | 37篇 |
1987年 | 11篇 |
1986年 | 10篇 |
1985年 | 19篇 |
1984年 | 19篇 |
1983年 | 17篇 |
1982年 | 5篇 |
1980年 | 5篇 |
1979年 | 7篇 |
1975年 | 3篇 |
1973年 | 5篇 |
1972年 | 4篇 |
1971年 | 3篇 |
1970年 | 4篇 |
1957年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
1.
2.
《Journal of diabetes and its complications》2022,36(8):108255
AimsThe effect of Glucagon-like peptide 1 receptor agonists (GLP1 RA) on diabetic retinopathy (DR) remains controversial. Previous reviews combined data from randomized clinical trials (RCTs) with or without cardiovascular (CV) benefits and did not address confounders, therefore may have generated misleading results. The study aimed to examine the effect of GLP1RA on DR in type 2 diabetes (T2DM) in RCTs with or without CV benefits and distinguish the effect by major confounders.MethodsWe conducted electronic searches of multiple databases and a manual search using references lists. We included 13 RCTs examining the effect of GLP1 RA on health outcomes/adverse events including DR or DR complications in T2DM. We performed a random-effects model meta-analysis.ResultsGLP1RA was associated with an elevated risk of rapidly worsening DR in four major RCTs with CV benefits in T2DM (OR 1.23, 95 % CI 1.05–1.44). The association between GLP1 RA and DR was significant in subgroups of RCTs with length over 52 weeks (1.2, 1.00–1.43), using placebo as a comparator (1.22, 1.05–1.42). In subgroups with patients who had T2DM ≥10 years (1.19, 0.99–1.42) or with subjects enrolled from multiple countries (1.2, 0.99–1.46), the association appeared to be evident but did not reach statistical significance.ConclusionsGLP1 RA including liraglutide, semaglutide, and dulaglutide are associated with an increased risk of rapidly worsening DR in RCTs with CV benefits. Further data from clinical studies with longer follow-up purposefully designed for DR risk assessment, particularly including patients of established DR are warranted. 相似文献
3.
《Survey of ophthalmology》2022,67(2):353-368
Dacryoadenitis is an inflammation of the lacrimal gland that may have various etiologies with similar presentations. Despite more recent elucidation of specific causes, the management has remained largely unchanged. Hence, the condition remains under biopsied with the rationale that empirical treatment with corticosteroids is effective for many of the causes. Dacryoadenitis, however, dacryoadenitis can be the presenting sign of an undiagnosed systemic disease and a mimick for lymphoma; hence, tissue diagnosis and systemic investigations play a vital role. A significant proportion of dacryoadenitis has a specific etiology, and IgG4-related dacryoadenitis is more frequently identified as a cause. We summarize the different types of immune-mediated dacryoadenitis, their clinical findings, histopathology, management, and prognosis. We have also highlighted and formulated practice guidelines for diagnosis and effective treatment based on the underlying systemic disease. 相似文献
4.
《Archives of physical medicine and rehabilitation》2022,103(6):1213-1221
In the United States, approximately 400,000 patients with acute stroke are discharged annually to inpatient rehabilitation facilities (IRFs) or skilled nursing facilities (SNFs). Typically, IRFs provide time-intensive therapy for an average of 2-3 weeks, whereas SNFs provide more moderately intensive therapy for 4-5 weeks. The factors that influence discharge to an IRF or SNF are multifactorial and poorly understood. The complexity of these factors in combination with subjective clinical indications contributes to large variations in the use of IRFs and SNFs. This has significant financial implications for health care expenditure, given that stroke rehabilitation at IRFs costs approximately double that at SNFs. To control health care spending without compromising outcomes, the Institute of Medicine has stated that policy reforms that promote more efficient use of IRFs and SNFs are critically needed. A major barrier to the formulation of such policies is the highly variable and low-quality evidence for the comparative effectiveness of IRF- vs SNF-based stroke rehabilitation. The current evidence is limited by the inability of observational data to control for residual confounding, which contributes to substantial uncertainty around any magnitude of benefit for IRF- vs SNF-based care. Furthermore, it is unclear which specific patients would receive the most benefit from each setting. A randomized controlled trial addresses these issues, because random treatment allocation facilitates an equitable distribution of measured and unmeasured confounders. We discuss several measurement, practical, and ethical issues of a trial and provide our rationale for design suggestions that overcome some of these issues. 相似文献
5.
6.
7.
8.
9.
《Survey of ophthalmology》2022,67(4):1031-1047
Uveal coloboma is a condition defined by missing ocular tissues and is a significant cause of childhood blindness. It occurs from a failure of the optic fissure to close during embryonic development and may lead to missing parts of the iris, ciliary body, retina, choroid, and optic nerve. Because there is no treatment for coloboma, efforts have focused on prevention. While several genetic causes of coloboma have been identified, little definitive research exists regarding the environmental causes of this condition. We review the current literature on environmental factors associated with coloboma in an effort to guide future research and preventative counseling related to this condition. 相似文献
10.
《The American journal of medicine》2022,135(7):879-888.e3
ObjectivesClinical trials have shown a beneficial effect from biological disease-modifying antirheumatic drugs (bDMARDs) on hand or axial bone loss in patients with rheumatoid arthritis; however, it is unclear if this translates to a reduced fracture risk. We investigated the effect of bDMARDs on osteoporotic fracture risk compared to no biological treatment in rheumatoid arthritis.MethodsA cohort of patients with rheumatoid arthritis aged 18+ from DANBIO was linked to population-based health registries in Denmark (2006-2016). Adopting a prevalent new-user design, we matched bDMARD users to bDMARD-naïve patients using time-conditional propensity scores. The risk of incident osteoporotic fractures (including hip, vertebrae, humerus, and forearm) was estimated among the matched patients by Cox proportional hazards models.ResultsOut of 24,678 patients with rheumatoid arthritis, 4265 bDMARD users were matched to the same number of bDMARD-naïve patients (mean age 56.2 years, 74% female). During follow-up, 229 osteoporotic fractures occurred among bDMARD users and 205 fractures among bDMARD-naïve patients (incidence rates 12.1 and 13.0 per 1000 person-years, respectively). The use of bDMARDs was not associated with a reduced risk of osteoporotic fractures among patients with rheumatoid arthritis (hazard ratio 0.97, 95% confidence interval 0.78-1.20), compared with no biological treatment. The risk estimates were similar for all osteoporotic fracture sites.ConclusionWe found no independent beneficial effect from using bDMARDs on reducing the risk of osteoporotic fractures in patients with rheumatoid arthritis. 相似文献